Trial Profile

Phase 2A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of CM-101 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2023 Results assessing the effect of CM-101 on disease related pathways through an analysis of proteomics data from the serum of patients from this study presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
24 Jun 2023 Results assessing the therapeutic potential of CM-101 in patients with NASH with fibrosis stages 1c, 2and 3, presented at the European Association for the Study of the Liver Congress 2023.
24 May 2023 According to a Chemomab Therapeutics media release, data from this study will be presented at the EASL Congress 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com